New lung cancer drug offers new hope for patients

Innovative drug shows promising signs in clinical trial

Stars Insider

26/02/25 | StarsInsider

HEALTH Illness

Akeso, a lesser-known Chinese biotech company founded nearly a decade ago, shook up the biotech world with its new lung cancer treatment in September 2024.

Ivonescimab, the innovative drug, outperformed Merck’s Keytruda in a trial conducted in China. Keytruda, a top-selling drug that has generated over US$130 billion in sales, has long dominated cancer treatment in the US.

Patients treated with Akeso’s drug, experienced 11.1 months before their tumors began to grow again, compared to just 5.8 months for Keytruda, according to clinical data shared at the World Conference on Lung Cancer.

This breakthrough is especially significant considering lung cancer’s status as one of the most common and dangerous cancers worldwide. For decades, diagnoses and deaths continued to rise due to the lack of a known cure. However, a shift is underway. As awareness of lung cancer's causes grows, the number of new cases has been declining since 2008. Despite this progress, lung cancer remains the most common cancer in many parts of the world, and much work still lies ahead.

Intrigued? Read on to learn everything you need to know to better protect yourself and your loved ones from lung cancer.

Campo obrigatório

Don’t miss out...


on the latest TV shows, movies, music, and exclusive content from the entertainment industry!

I accept terms & conditions and privacy policy.
I want to receive Exclusive Offers from partners (advertising)

You can easily unsubscribe at any time
Thank you for subscribing